Formulation of sustained release drug delivery of carbamazepine to modulate release of drug to achieve specific clinical purpose

Carbamazepine (CBZ) is a water-insoluble anti-epileptic drug of choice for the treatment of partial and tonic clonic seizure disorders. In the present study, an attempt made to develop the bilayer matrix tablets of CBZ using EUDRAGIT RSPO, RLPO and HPMC K100M.The sustained release pattern of CBZ evaluated by in-vitro drug release for 24 h. In the immediate release layer contains crosscarmellose sodium as superdisintegrant and water immiscible polymers such as Eudragits in the sustaining layer. Formulations were evaluated for the release of CBZ over a period of 24 h using USP type-I dissolution apparatus and were compared to the pharmacopoeial standards. The prepared formulations gave an initial burst effect to provide loading dose of the drug followed by sustained release for 24 h from the sustaining layer of matrix embedded tablets. The drug release from the formulation F11 was increased satisfactorily upto 102% (10%HPMC K100M) till 24 h which meet the specifications as specified in the USP. In-vitro dissolution kinetics of the formulation was found to follow first order and the release mechanism was best fitted in Korsemeyer-Peppas model via Fickian diffusion controlled mechanism after the initial burst release.

Author(s): S. Vasudeva Murthy

Abstract | PDF

Share This Article